Managers / Q2 2023 · view latest →
Sivik Global Healthcare LLC
CIK 0001596452 · 133 TACONIC RD, GREENWICH, CT, 06831 · 203-769-8600
Reported Value
$428M
Q2 2023
Positions
43
Filings on Record
30
2019–present window
Filed
Aug 9, 2023
original filing
Summary
Sivik Global Healthcare LLC reported $428M in U.S.-listed holdings across 43 positions for Q2 2023.
Its largest position, XBI, represents 4.9% of the portfolio.
Compared with Q1 2023, the fund opened 8 new positions and exited 5.
Portfolio Metrics
Turnover
+11.5%
vs prior filed quarter
Top-10 Concentration
+22.8%
share of reported value
Largest Position
+4.9%
Spdr S P Biotech Etf
New / Exited
8 / 5
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 50.8% · $217M
- ETP · 46.3% · $198M
- ADR · 2.3% · $10M
- Other · 0.5% · $2M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SPYSPDR S&P 500 ETF Trust | NEW | +400.0K | 400.0K | +$177M | $177M |
| Catalent Inc | NEW | +70.0K | 70.0K | +$3M | $3M |
| Charles River Laboratories In | NEW | +13.0K | 13.0K | +$3M | $3M |
| Stevanato Group SpA | NEW | +70.0K | 70.0K | +$2M | $2M |
| AVTRAvantor Inc | NEW | +75.0K | 75.0K | +$2M | $2M |
| CYHCommunity Health Systems Inc | NEW | +300.0K | 300.0K | +$1M | $1M |
| ARGXArgenx SE | NEW | +3.0K | 3.0K | +$1M | $1M |
| GRFSGrifols SA | NEW | +62.8K | 62.8K | +$576,000 | $576,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2023
42 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | XBISPDR S&P Biotech ETFhistory → | Cash Securities | 4.87% | $21M | 250.0K |
| 2 | THCTenet Healthcare Corphistory → | Cash Securities | 2.66% | $11M | 140.0K |
| 3 | BSXBoston Scientific Corphistory → | Cash Securities | 2.02% | $9M | 160.0K |
| 4 | UHSUniversal Health Services Inchistory → | Cash Securities | 1.94% | $8M | 52.5K |
| 5 | LLYEli Lilly & Cohistory → | Cash Securities | 1.92% | $8M | 17.5K |
| 6 | NVONovo Nordisk A/Shistory → | Cash Securities | 1.89% | $8M | 50.0K |
| 7 | CAHCardinal Health Inchistory → | Cash Securities | 1.88% | $8M | 85.0K |
| 8 | ZBHZimmer Biomet Holdings Inchistory → | Cash Securities | 1.87% | $8M | 55.0K |
| 9 | BDXBecton Dickinson & Cohistory → | Cash Securities | 1.85% | $8M | 30.0K |
| 10 | SGRYSurgery Partners Inchistory → | Cash Securities | 1.84% | $8M | 175.0K |
| 11 | HUMHumana Inchistory → | Cash Securities | 1.83% | $8M | 17.5K |
| 12 | CORAmerisourceBergen Corphistory → | Cash Securities | 1.80% | $8M | 40.0K |
| 13 | ISRGIntuitive Surgical Inchistory → | Cash Securities | 1.80% | $8M | 22.5K |
| 14 | SYKStryker Corphistory → | Cash Securities | 1.78% | $8M | 25.0K |
| 15 | HCAHCA Healthcare Inchistory → | Cash Securities | 1.77% | $8M | 25.0K |
| 16 | MCKMcKesson Corphistory → | Cash Securities | 1.75% | $7M | 17.5K |
| 17 | BAXBaxter International Inchistory → | Cash Securities | 1.71% | $7M | 160.0K |
| 18 | EHCEncompass Health Corphistory → | Cash Securities | 1.58% | $7M | 100.0K |
| 19 | ELVElevance Health Inchistory → | Cash Securities | 1.56% | $7M | 15.0K |
| 20 | ABTAbbott Laboratorieshistory → | Cash Securities | 1.53% | $7M | 60.0K |
| 21 | IQVIQVIA Holdings Inchistory → | Cash Securities | 1.45% | $6M | 27.5K |
| 22 | S24Select Medical Holdings Corphistory → | Cash Securities | 1.42% | $6M | 190.0K |
| 23 | DHRDanaher Corphistory → | Cash Securities | 1.40% | $6M | 25.0K |
| 24 | MRKMerck & Co Inchistory → | Cash Securities | 1.35% | $6M | 50.0K |
| 25 | CICigna Group/Thehistory → | Cash Securities | 1.31% | $6M | 20.0K |
| 26 | MDTMedtronic PLChistory → | Cash Securities | 1.24% | $5M | 60.0K |
| 27 | ICLRICON PLChistory → | Cash Securities | 1.17% | $5M | 20.0K |
| 28 | VRTXVertex Pharmaceuticals Inchistory → | Cash Securities | 1.15% | $5M | 14.0K |
| 29 | UNHUnitedHealth Group Inchistory → | Cash Securities | 1.12% | $5M | 10.0K |
| 30 | ACHCAcadia Healthcare Co Inchistory → | Cash Securities | 1.12% | $5M | 60.0K |
| 31 | BMRNBioMarin Pharmaceutical Inchistory → | Cash Securities | 1.01% | $4M | 50.0K |
| 32 | TMOThermo Fisher Scientific Inc | Cash Securities | 0.92% | $4M | 7.5K |
| 33 | Catalent Inc | Cash Securities | 0.71% | $3M | 70.0K |
| 34 | BIIBBiogen Inc | Cash Securities | 0.67% | $3M | 10.0K |
| 35 | Charles River Laboratories In | Cash Securities | 0.64% | $3M | 13.0K |
| 36 | Stevanato Group SpA | Cash Securities | 0.53% | $2M | 70.0K |
| 37 | AVTRAvantor Inc | Cash Securities | 0.36% | $2M | 75.0K |
| 38 | ALNYAlnylam Pharmaceuticals Inc | Cash Securities | 0.36% | $2M | 8.0K |
| 39 | CYHCommunity Health Systems Inc | Cash Securities | 0.31% | $1M | 300.0K |
| 40 | ARGXArgenx SE | Cash Securities | 0.27% | $1M | 3.0K |
| 41 | GRFSGrifols SA | Cash Securities | 0.13% | $576,000 | 62.8K |
| 42 | SRPTSarepta Therapeutics Inc | Cash Securities | 0.02% | $93,000 | 811 |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $132M | 34 | Apr 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $345M | 49 | Jan 21, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $344M | 44 | Oct 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $368M | 46 | Jul 25, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $185M | 31 | Apr 22, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $190M | 38 | Jan 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $236M | 35 | Nov 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $278M | 38 | Jul 29, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $427M | 47 | May 1, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $239M | 39 | Feb 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $198M | 33 | Nov 7, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $428M | 43 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $233M | 40 | May 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $213M | 39 | Feb 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $180M | 41 | Nov 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $176M | 38 | Aug 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $242M | 49 | May 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $233M | 45 | Feb 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $419M | 43 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $512M | 49 | Aug 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $274M | 47 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $245M | 38 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $232M | 38 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $302M | 52 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $253M | 40 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $269M | 50 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $198M | 45 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $414M | 62 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $271M | 61 | May 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $186M | 48 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.